The Global Tuberculosis Strategies - Epidemiologic Statistics, Screening and Diagnostic, Therapeutics and Strategic Assessment of Tuberculosis Market Potential.LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its catalogue. Global Tuberculosis Strategies http://www.reportlinker.com/p049679/tuberculosis.html The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated this report, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. There are primarily three focal points for the development of strategy for combating tuberculosis: potential market, epidemiology (tuberculosis patient trends) and technology, and how diagnostic and pharmaceutical companies can incorporate these focal points into strategy. Lack of proper diagnosis is one of the barriers to tuberculosis treatment. The publisher goes into detail about screening techniques and the potential market for diagnostic products. In addition, treatment markets are defined for major regions of the world. The report covers these points in detail and presents the most authoritative look at the global tuberculosis threat, strategies to combat tuberculosis, and the market opportunities that can be created in tuberculosis treatment. As part of its coverage, the report includes: Extensive Tuberculosis Etiology necessary to understand this unique disease. Epidemiologic Statistics including 30 Tables of Incidence, Prevalence and Mortality Statistics by Region and by Type of Tuberculosis. Theoretical Market Sizes for Screening/Diagnosis as well as Treatment by Region and by Type of Tuberculosis (MDR MDR, n See multidrug resistance. MDR, n the abbreviation for minimum daily requirement, specifically the Minimum Daily Requirements for Specific Nutrients compiled by the United States Food and Drug Administration. and non-MDR). Complete overview of Tuberculosis Screening Procedures. Review of Products used for treatment of Tuberculosis. A Glossary of Important Terms. A truly global round-up, the report focuses in detail on the following regions: Africa The Americas Eastern Mediterranean Europe Southeast Asia Western Pacific Marketing directors, product managers, sales managers and business development executives in both diagnostic and pharmaceutical companies will benefit from this unique resource. Table of content CHAPTER ONE: Executive Summary Market Potential Epidemiology Technology Scope and Methodology CHAPTER TWO: The Basics of Tuberculosis Tuberculosis Fundamentals Etiology and Pathogenesis Etiology Pathogenesis Primary Infection Secondary/Disseminated Tuberculosis Tuberculosis Epidemiology General Epidemiology Molecular Epidemiology CHAPTER THREE: Tuberculosis Screening and Diagnosis Overview Skin Testing Laboratory Testing Adenosine Deaminas Nucleic Acid Amplification Tests (NAAT NAAT Nucleic Acid Amplification Test NAAT North American Aviation Trilateral (Canada) NAAT Nucleic Acid Amplification Techniques NAAT New Americans Against Tobacco NAAT NATO Anti-Armor Trials )/Molecular Diagnostics Interferon- Microbiological Studies Culture - vs - Non-Culture Testing Culture-Based Systems Non-Culture Methods Nucleic Acid Amplification (NAA NAA Nomina Anatomica Avium. ) Diagnostic development must be based on assessment of medical needs. Specifications must be defined. The tests should be designed to be used where the patients are. There is insufficient knowledge about local conditions: High-tech strategies should not be force-fit to low-tech settings: Simplification is needed in the interim: Fundamental research questions must be addressed. Public leadership is required in priority setting: Access and pricing issues must be clarified. CHAPTER FOUR: Tuberculosis Therapeutics Tuberculosis Drugs: First Line Isoniazid isoniazid (ī'sōnī`əzĭd), drug used to treat tuberculosis. Also known as isonicotinic acid hydrazide, isoniazid is the most effective antituberculosis drug currently available. (INH INH abbr. isoniazid isoniazid (INH) Isotamine (CA), PMS Isoniazid (CA) Pharmacologic class: Isonicotinic acid hydrazide Therapeutic class: Antitubercular ) Rifampin rifampin (rĭfăm`pĭn), antibiotic used in the treatment of tuberculosis. It is also used to eliminate the meningococcus microorganism from carriers and to treat leprosy, or Hansen's disease. (RIF) Ethambutol ethambutol /etham·bu·tol/ (e-tham´bu-tol) an antibacterial, specifically effective against Mycobacterium; used with one or more other antituberculous drugs in the treatment of pulmonary tuberculosis, administered as the (EMB EMB eosin-methylene blue. ) Pyrazinamide (PZA PZA Pyrazinamide, see there ) Tuberculosis Drugs: Second Line Aminoglycosides Fluoroquinolones Polypeptides Thioamides Cycloserine cycloserine /cy·clo·ser·ine/ (-se´ren) an antibiotic produced by Streptomyces orchidaceus or obtained synthetically; used as a tuberculostatic and in treatment of urinary tract infections. p-Aminosalicylic Acid Other Drugs Management of Relapse, Treatment Failure, and Drug Resistance Treatment of Tuberculosis in HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients Multi-Drug Resistance in Tuberculosis Therapeutic Progress CHAPTER FIVE: Strategic Assessment of Tuberculosis Market Potential Global Tuberculosis Strategies United States Agency for International Development The United States Agency for International Development (or USAID) is the U.S. government organization responsible for most non-military foreign aid. An independent federal agency, it receives overall foreign policy guidance from the U.S. (USAID USAID United States Agency for International Development USAID Agencia de los Estados Unidos para el Desarrollo Internacional (Spanish) ) The Stop TB Partnership Global Drug Facility (GDF) APPENDIX: Glossary More market research reports? Go to http://www.reportlinker.com http://www.reportlinker.com/Rss/en/index.htm http://www.reportlinker.com/Rss/fr/index.htm http://blog.reportlinker.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion